

The Risk & Compliance Pharma & Life Sciences Conference
1st October, One America Square, London



Welcome To The Risk & Compliance For Pharma & Life Sciences Conference

Official Event Programme

Please note that the following timings are flexible. Due to the nature of a live event, the conference chairs and organisers will be updating the timings throughout the day to adapt to speakers running over time, late arrivals, last minute changes and extending popular sessions. Please rest assured we will do our utmost to adapt and to accommodate all live changes.

Organised By:



08.30 Registration & Informal Networking

09.00 GIC Welcome & Morning Chair's Opening Remarks

Kiki Merakli, Global Corporate Functions, Ethics & Compliance, **Takeda**



Regulatory Updates & Trends – Panel & Q&A

09:10 Unpack Critical Emerging Regulatory Shifts, Stay Ahead Of The Curve & Unpack What's Next For Compliance Professionals in 2026 & Beyond

- Drive the shift towards agile and risk-based regulatory frameworks to proactively tackle regulatory compliance developments and challenges
- Unpack the latest legislative and enforcement developments and translate regulatory change into clear and actionable priorities
- Analyse the potential impact of new and upcoming frameworks such as the EU AI Act and data protection policies to identify where scrutiny is intensifying and how professionals can proactively assess their controls and frameworks
- Look beyond immediate updates to assess long-term regulatory shifts to equip risk and compliance professionals with forward-looking strategies to remain agile and resilient in an increasingly complex global and regulatory landscape

Dr Corlia Van Der Walt, Director: R&D Partnerships & Legal Compliance, **AstraZeneca**



The Risk & Compliance Pharma & Life Sciences Conference
1st October, One America Square, London

Alicia White, Director, **PMCPA**



Dhananjay Bhavsar, Quality Regulatory Compliance Inspection & Audits Expert, **Sandoz**



Richard Hodge, Partner, **Dechert**



09:40 Building Agentic AI Systems Inside A Regulated Environment

- Regulation Overview
- Regulation and Governance at global level
- Proposed Framework for Building Agentic AI Systems Inside A Regulated Environment

Jordi Escayola, Global Head of Advanced Analytics & AI, **Opella**



Signals In The Noise

10.00 Signals In The Noise: An Intelligence-Led Framework for Partnership Vetting

Megan Ardis, Senior Brand Risk Intelligence Analyst and Subject Matter Expert, **Resolver**, a Kroll Business



10.20 Morning Refreshment Break With Informal Networking

AI User Cases & Implementation

10:50 Achieve Effective AI Implementation & Master Regulatory Framework Development To Accelerate Organisation-Wide Adoption

- What are the current established uses of AI in compliance and what new trends are emerging? Deep dive into the emerging best practices for AI adoption to enhance operations and efficiencies across the organisation
- Monitor the regulatory challenges around adopting new technologies and create coherent and comprehensive strategies for internal AI policies that enable effective implementation
- Keeping the human in the loop: from updated training techniques to promoting digital literacy across the workforce, how can responsible AI behaviours best be encouraged and monitored to ensure awareness of patient safety, data protection and bias mitigation?
- What lessons can be learned from AI implementation within the pharmaceuticals industry? Unpack the insights and troubleshooting from AI adoption to reframe your approaches in the future

Enrique Grande Jarque, Head of Ethics & Compliance Iberia, **Takeda**



Pharmaceutical compliance.

Engage confidently from owned channels to the wider web, with triple-checked pharmacovigilance designed to exceed regulatory requirements.



Built for Confident Engagement and Trusted Compliance

FDA and EMA certified, fully compliant vendor aligned with the new AI guiding principles. We deliver an audit-ready compliance framework with 10-year data retention, built to meet the latest 2026 FDA E2D mandates for pharma vendor partnerships.



100% SLA adverse event detection

Capture every adverse event with pharmacovigilance-trained analysts and triple-checked accuracy. Gain control with automated, prioritized alerts, centralized reconciliation reports, and 10-year data retention.



Fully managed & scalable service

Grow your campaigns while we handle compliance 24/7, 365 days a year. With scalable FDA and EMA compliant coverage across brands, markets, and regions in 25+ languages.



Global & comprehensive monitoring

Maintain a safe digital presence with active moderation on owned and paid channels. We continuously monitor the wider web, Digital Opinion Leaders, and 2-way messaging apps like WhatsApp and Viber.



Executive-ready reporting

Go beyond basic keyword detection to understand the why. Access intelligence reports built by experts for clear, strategic insights into hidden vulnerabilities and emerging online risks.



Trusted by global marketing and communication leaders



Resolver's team understands our product better than most vendors I've ever worked with. The coverage, the proactivity, and the care you show - it's rare to find. When other teams hear Resolver, it's always a positive association."

*Senior Manager of Digital & Social Engagement,
Global Pharmaceutical Brand*

Made for Marketers. Trusted by Compliance.

resolver.com



Data Privacy, Analysis & Integrity – Delegate Discussion

11:10 Strengthen Data Privacy Governance & Utilise Advanced Analytics To Mitigate Risk & Safeguard Patient Trust

- Leverage advanced analytics and data insights responsibility while maintaining strict adherence to GDPR and emerging global data privacy regulations
- Identify, assess and mitigate data risks through techniques such as validation controls, robust oversight and monitoring mechanisms
- Build resilient and comprehensive systems that protect data integrity, reinforce regulatory confidence and sustain patient trust in an increasingly data-driven pharmaceutical landscape
- Strengthen data governance frameworks to ensure secure and compliant collection, storage and analysis of sensitive data

Compliance Cultures - Panel & Q&A

11.30 Embed Integrity At Every Level & Transform Compliance From Obligation To Organisational Mindset

- What is a culture of compliance? Define and measure what “good” looks like through tangible indicators of a healthy risk and compliance culture and embed integrity by design
- Empower leadership to set the tone from the top and model ethical decision-making, reinforce accountability and foster a productive and proactive approach to compliance across every level of the organisation
- Rethink training to drive real behavioural change and develop effective metrics to track data, feedback and measurable outcomes for these new strategies
- Leverage behavioural science, digital tools, and AI to drive measurable change in training effectiveness
- Foster trust in measures such as speak up culture, ensure consistent investigation standards and continuously monitor culture beyond tick-box assessments and exercises

The Risk & Compliance Pharma & Life Sciences Conference
1st October, One America Square, London

Jelena Danilovic, Head of Compliance, **Hemofarm A.D.**



Nicola Galtieri, Head of Global Ethics & Compliance, **Kedrion Biopharma**



Antonios Roussos, Head of Ethics & Compliance Global Excellence & Innovation, **Astellas**



Zoe Buch, Senior Director, TPRM & Enterprise Compliance, EMEA & Americas, **Johnson & Johnson**



Anastasiya Troyan, Senior Director External Engagements, **Novartis**



Compliance, without the complexity.

Independent medical and compliance support for pharmaceutical companies across the UK, Ireland and above-country.

-
- 01 Final Signatory & medical review support
 - 02 PMCPA complaints, audits, SOPs & ABPI training
 - 03 Consultants with 10+ years' signatory & compliance experience
-

I'M HERE TODAY

Come and say hello

Sarah Hollywood · Managing Director

Find me at the breaks, or text 07702 037446.

sarah.hollywood@hollywoodmedico.co.uk



How we help

Signatory & review

Final Signatory support and medical review, on demand or embedded in your team.

PMCPA complaints

Managing PMCPA complaints and facilitating inter-company dialogue.

Governance

Compliance audits, SOP development and compliance consultancy.

Training & advice

ABPI Code training and strategic advice for medical and commercial teams.

COMPETITIVE, FLEXIBLE RATES

Only pay for the support you use.

Ad hoc

Pay as you go, when you need it

Pro rata

Regular days each month

Project

Fixed scope for audits, SOPs or training

Independent

Impartial, objective advice

In-depth experience

UK, Ireland & above-country

Responsive

Fast, high-quality output



45 Albemarle Street, Mayfair, London W1S 4JL

hollywoodmedico.co.uk
info@hollywoodmedico.co.uk
+44 (0)20 3668 6652

Third-Party Risk Management

12.10 Elevate Third-Party Risk Management Frameworks To Ensure Rigorous Compliance, Strengthen Oversight & Build Resilient Supply Chains

- Move beyond reactive compliance monitoring by utilising assessment data, internal audits and continuous oversight to enact measurable improvements and optimise third-party performance
- Develop proactive due diligence approaches to identify vulnerabilities early and mitigate regulatory and operational threats
- Anticipate the next evolution of third-party risk management by addressing emerging geopolitical, regulatory and operational risks while building partnerships founded on trust and resilience

Lucy Sales, Senior Director – Risk & Compliance, **AstraZeneca**



Rebuilding HCP Compliance With Agentic AI

12.30 Case Study - Rebuilding HCP Compliance With Agentic AI

- **Why HCP compliance needs to change:** Increasing transparency requirements and DOJ expectations are making it essential for reviewers to see a physician's complete engagement history at the point of approval.
- **One entry point, one HCP profile:** See how a lean Legal & Compliance team brings consulting, events, sponsorships, and grants into a single conversational workflow, replacing fragmented Excel, forms, emails, and reporting tools.
- **AI with human oversight:** Explore why the team chose an AI-native platform, how compliance policies become traceable decision trees, and where AI recommendations end and human approval begins.
- **From transparency to automation:** Follow a live demo from the initial request through conditional approval and the physician's full history—and learn a practical model for increasing automation without sacrificing auditability.

The Risk & Compliance Pharma & Life Sciences Conference
1st October, One America Square, London

Erik Krauter, Co-Founder & CTO, **Bayshore**



BAYSHORE

12.45 Lunch & Informal Networking For Speakers, Delegates & Partners

Breakout session during lunch: **Cross-Border Activity Management**

Alexis Pagé, Business Ethics Director, **Ipsen**



13.45 Afternoon Chair's Opening Remarks

Karen Allman, Head, Global Compliance, **Formerly ViiV Healthcare**



Geopolitics & International Risk – Panel Q&A

13.55 Embed Proactive & Strategic Approaches To Navigate Geopolitical Uncertainty Amidst A Volatile Global Landscape

- Leverage your logistics: examine how to systematically monitor geopolitical disruption and anticipate the potential impacts within your organisation and functions
- Craft agile frameworks & safeguard operational continuity while upholding ethical standards and compliance obligations in areas facing instability or uncertainty
- Move beyond awareness to action – assess the implications of political and regulatory developments across the supply chain, market access and third-party partnerships
- Promote proactivity over reactivity by designing agile governance structures and strategies that enable confident decision-making in uncertain times
- Mitigate the risk of data loss and digital disruption across operations and supply chains in conflict scenarios

Tetiana Isaieva, Head of Compliance EEMEAIS, **Roche**



Marion Pillwein, Senior Director Quality Assurance, **Octapharma**




Liam O'Shaughnessy, Compliance Director – External Affairs & Comms & Global Commercial Strategy, **ViiV**



The Risk & Compliance Pharma & Life Sciences Conference
1st October, One America Square, London

Michelle Koleosho, Legal Director, **MSD**



Natasha Martin, Director of Product, **Ethixbase360**



Geopolitics & International Risk – Delegate Discussion

**14.35 Embed Proactive & Strategic Approaches To Navigate Geopolitical Uncertainty
Amidst A Volatile Global Landscape – Delegate Discussion**

We would encourage you all to enter into the spirit of the day and to share ideas with fellow delegates. We understand there might be commercial sensitivities behind discussing strategies, however, there is a lot to be gained from sharing theories, mindsets and abstract situations – the person sat next to you might just have that fresh outlook which unlocks new potential!

1. What was your biggest takeaway from the panel, and what, if anything, challenged your current thinking?
2. Thinking about your own organisation, what is one area where you feel you are well prepared for uncertainty — and one area where you would like to see greater resilience?
3. Did anything you heard today make you reconsider how your organisation balances preparedness with the need to remain agile? What would you do differently as a result?
4. What is one idea, approach or lesson from today's discussion that you could take back to your organisation and put into practice?

14:55 Afternoon Refreshment Break With Informal Networking

15.30 Resolver Announce Their Competition Winner!

Monitoring & Auditing

15.35 Utilise Technologies & Monitoring Techniques To Drive Continuous Assurance & Transform Oversight Into Strategic Advantage

- How can AI-enabled risk sensing compress assessment cycles and what governance is required to trust and act on those signals?
- Which decision-grade metrics should boards require to oversee data integrity, model performance, and compliance in near real time?
- How do organisations redesign assurance to run continuous checks without blurring accountability across the lines of defence?
- How do we combine real-time analytics and risk-based sampling with escalation protocols, so issues are detected early and acted on safely?
- What must the board approve when assurance becomes intelligent?

Stefan Nickels, Global Director Internal Audit, **Daiichi Sankyo**



HCP Interaction & Engagement– Panel Q&A.

15.55 Define Powerful Strategies For Embedding Integrity, Transparent & Control Across All HCP Touchpoints

- Redefine HCP engagement models without compromising integrity: maintain a clear and defensible distinction between scientific exchange and commercial influence across every channel
- Prevent the blurring of promotional vs non-promotional lines and uphold compliance standards across diverse interaction platforms to cultivate compliant relationships with HCPs
- Anticipate regulatory, enforcement and media scrutiny by utilising data-driven monitoring and proactive risk identification to protect both reputation and patient trust

Sylvia Oba, Global Markets Ethics, Compliance & Privacy Director, **Servier**



Aymeric Lannoy, Head of Compliance & Ethics Benelux, Switzerland & Austria – Associate Director, **Bristol Myers Squibb**



Pia Weckendorf, Head of Internal Audit, **Grünenthal Group**



The Risk & Compliance Pharma & Life Sciences Conference
1st October, One America Square, London

16.35 Afternoon Chair's Closing Remarks & Official Close Of Conference.

Karen Allman, Head, Global Compliance, **Formerly ViiV Healthcare**



16:45 Official Close Of Conference